Artificial lung market seen reaching $4.27 billion by 2030

The global artificial lung market is projected to grow from $2.58 billion in 2025 to $4.27 billion by 2030, driven by rising respiratory disease cases, demand for critical care support and wider use in transplant and emergency care. North America was the largest market in 2025, according to The Business Research Company.

Why it matters: - Artificial lung devices are gaining importance as respiratory disease, critical care demand and transplant volumes put more pressure on life-support systems. - The forecast points to steady expansion in a market tied to emergency care, cardiothoracic surgery and organ transplantation.

What happened: - The Business Research Company projected the artificial lung market will rise from $2.58 billion in 2025 to $2.88 billion in 2026. - The report forecasts the market will reach $4.27 billion by 2030. - The projected growth rate is 11.6% from 2025 to 2026 and 10.4% through 2030. - North America was the largest artificial lung market in 2025. - The report said the market covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Artificial lungs are designed to oxygenate blood and remove carbon dioxide. - The devices are used for patients with severe respiratory failure and during surgeries that require temporary suspension of heart and lung function. - The market’s recent growth has been linked to more acute respiratory failure cases, early use of heart-lung machines in cardiothoracic surgery, higher organ transplant volumes, membrane artificial lung advances and broader use of extracorporeal life support. - The report expects future demand to come from critical care life-support needs, portable and compact artificial lung systems, improved oxygenation membrane materials, emergency and trauma care use, and minimally invasive extracorporeal support. - The company highlighted trends including wider use in severe respiratory failure, more use in complex lung and cardiac transplant procedures, preference for temporary and minimally invasive support over transplantation, and portable units built for emergency settings. - The report said membrane-based artificial lung technologies are being developed to improve gas exchange and extend support time. - In June 2024, the Australian Institute of Health and Welfare reported that about 8.5 million Australians, or 34% of the population, had chronic respiratory diseases. - The same data set cited about 2.8 million people with asthma and 638,000 people with chronic obstructive pulmonary disease. - North America’s lead was attributed to advanced healthcare infrastructure, ongoing research and development and high adoption of cutting-edge medical technologies. - The report also included market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and key technology and future trend analysis. - The report offered a free sample and full report through the company’s announcement and the full market report.

Between the lines: - The forecast suggests artificial lungs are moving from niche surgical support toward broader critical care use. - Portable and minimally invasive systems appear to be a key commercial and clinical focus, which could expand adoption outside traditional hospital settings. - Rising respiratory disease prevalence helps explain why the market outlook remains strong even before newer device categories fully mature.

What's next: - The report expects innovation in oxygenation membranes, compact device design and transport-friendly systems to shape the next phase of the market. - Wider use in emergency and trauma care could become a key growth driver if development and adoption continue. - The business contact listed for the report is Saumya Sahay at The Business Research Company.